Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
HK Stock Connect Healthcare ETF (520510) Rises Over 2% Intraday; Schrodinger Holdings Reports First Annual Profit
On March 17, the Hong Kong Stock Connect Healthcare ETF (520510) temporarily rose over 2% during trading. China Sanjiu Pharmaceutical and Ying En Bio led the gains, with Jingtai Holdings, WuXi AppTec, and Kingsray Biotech also among the top performers.
In terms of news, domestic AI pharmaceutical platform company Jingtai Holdings released a profit forecast for 2025: total revenue is expected to be no less than 780 million yuan, a year-on-year increase of over 193%; net profit after tax and profit attributable to the company’s equity holders are both at least 100 million yuan, successfully turning losses into profits. Jingtai Holdings is the first AI application stock listed in Hong Kong to achieve annual profitability.
Aijian Securities believes that the long-term trend of innovation and development in China’s pharmaceutical industry remains unchanged. After market clearing, there may be opportunities for long-term strategic positioning. The industry trend of Chinese innovative drugs going global remains optimistic, with a focus on tracking investment opportunities in core sectors such as ADC, bispecific antibodies, small nucleic acids, and weight-loss drugs.